PTC Therapeutics, Inc. (PTCT:NASDAQ) closed at $60.59 on October 23, 2026, down 3.89% on the day. The stock trades 33.3% below its 52-week high of $90.87 and 3.0% above its 52-week low of $58.80. Over the past year, it lost 8.8%. PTC Therapeutics, Inc. is part of the Health Care sector (Major Pharmaceuticals).
In 252 trading sessions since October 23, 2025, PTCT closed higher on 123 days (49%). Its best day was May 8, 2026 (+14.27%) and its worst was July 31, 2026 (-9.94%). The stock moved 10% or more in a single session 1 time. It opened at least 5% above the previous day's high 1 time.
PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of orally administered, small molecule drugs that target post-transcriptional control processes. The company's lead product is Translarna (ataluren), for the treatment of nonsense mutation Duchenne muscular dystrophy in ambulatory patients; and which is in phase III clinical trials to treat cystic fibrosis caused by nonsense mutations. It also develops Translarna, which is in Phase II clinical trials for the treatment of mucopolysaccharidosis type I caused by nonsense mutation, nonsense mutation aniridia, and nonsense mutation Dravet syndrome/CDKL5; and RG7916 that is in Phase I clinical trials to treat spinal muscular atrophy. In addition, the company's product candidate in cancer stem cell program include PTC596, an orally bioavailable and potent small molecule, which has completed phase I clinical trials that targets tumor stem cell populations by reducing the activity and amount of a protein called BMI1. PTC Therapeutics, Inc. has collaborations with F. Hoffman-La Roche Ltd and Hoffman-La Roche Inc., and the Spinal Muscular Atrophy Foundation to develop and commerci...
Find more stocks like PTCT with the Spikes, Gaps, Breakouts and Performance Tracker scanners.
Based on end-of-day data. For information only, not investment advice.